Programme

Presentation synopsis:

Clinical case 3: Cancer drugs DDIs

Drug-drug interactions (DDI) between treatments of HIV infection and cancer disease are frequent and often clinically relevant, requiring a particular attention to avoid severe acute toxicities or therapeutic failure. This high potential of DDI highlights the urgent need for their evaluation in HIV-infected patients who are initiating a treatment for their cancer disease either with chemotherapy or other associated treatments. For that reason, multidisciplinary staffs are strongly advised to discuss the most appropriate therapeutic strategy in order to both preserve virologic efficacy and prevent the occurrence of severe acute toxicities, which may be life-threatening. We will discuss a clinical case from our French national OncoVIH multidisciplinary staff summarizing such DDI issues between both antiretrovirals and other comedications and the management of the cancer disease.

Speaker biography:

Caroline Solas is a pharmacologist (Pharmacy Degree in 2001, PhD in Clinical Pharmacology in 2006, Aix-Marseille University) involved in the management of HIV-infected and HIV-HCV coinfected patients. She is in charge of the Therapeutic Drug Monitoring of antiretrovirals/antivirals drugs in her lab and every week joins a multidisciplinary staff along with virologist and physicians to discuss patients’ clinical management.

Her research is focused on the control of the pharmacokinetic-pharmacodynamic variability of antiretrovirals and antivirals drugs in the area of HIV, hepatitis infections and other emergent viral diseases. It includes drug pharmacokinetics, determination of pharmacological and genetic determinants of the drug response using population PK and PK-PD modeling and drug-drug interactions.


Active member of the French Society of Pharmacology and Therapeutics and of the ANRS (French national agency for research on AIDS and viral hepatitis trials), she currently serves on the ANRS committee guidelines and is the coordinator of the Pharmacology workgroup. She is a member of the scientific committee of the ANRS Hepavih cohort and of the CancerVIH group (INCA grant) and the lead pharmacologist of the ONCOVIH national multidisciplinary staff and other ANRS trials (ANRS EP45 AGING; ANRS HC27 BOCEPREVIH).


Registration

Registration is open

Second Announcement

Take a look

Call for abstracts

Submissions are closed